AKT1 and neoplasm: MK-2206, a highly selective non-ATP-competitive allosteric Akt inhibitor and GSK690693 a novel ATP-competitive, pan-Akt kinase inhibitor selective for the Akt isoforms were two agents tested for anti-tumor activity by the PPTP (Carol et al., 2010b; Gorlick et al., 2012a).